JP2017534254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534254A5 JP2017534254A5 JP2017513709A JP2017513709A JP2017534254A5 JP 2017534254 A5 JP2017534254 A5 JP 2017534254A5 JP 2017513709 A JP2017513709 A JP 2017513709A JP 2017513709 A JP2017513709 A JP 2017513709A JP 2017534254 A5 JP2017534254 A5 JP 2017534254A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- chain
- isolated human
- human antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 15
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 10
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 101000717877 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-A Proteins 0.000 claims 7
- 101000717881 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-B Proteins 0.000 claims 7
- 101000643078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S9-A Proteins 0.000 claims 7
- 101000729607 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S9-B Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 4
- 208000023958 prostate neoplasm Diseases 0.000 claims 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 108010059074 monomethylauristatin F Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000002619 cytotoxin Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 206010027457 Metastases to liver Diseases 0.000 claims 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 1
- 229960000853 abiraterone Drugs 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 229960004671 enzalutamide Drugs 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 230000034701 macropinocytosis Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- -1 radionuclides Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049973P | 2014-09-12 | 2014-09-12 | |
| US62/049,973 | 2014-09-12 | ||
| PCT/US2015/049492 WO2016040683A1 (en) | 2014-09-12 | 2015-09-10 | Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113065A Division JP7207753B2 (ja) | 2014-09-12 | 2020-06-30 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534254A JP2017534254A (ja) | 2017-11-24 |
| JP2017534254A5 true JP2017534254A5 (enExample) | 2018-10-18 |
| JP6730260B2 JP6730260B2 (ja) | 2020-07-29 |
Family
ID=55459583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513709A Active JP6730260B2 (ja) | 2014-09-12 | 2015-09-10 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
| JP2020113065A Active JP7207753B2 (ja) | 2014-09-12 | 2020-06-30 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113065A Active JP7207753B2 (ja) | 2014-09-12 | 2020-06-30 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10533056B2 (enExample) |
| EP (1) | EP3191524A4 (enExample) |
| JP (2) | JP6730260B2 (enExample) |
| KR (2) | KR102786695B1 (enExample) |
| CN (2) | CN114106179B (enExample) |
| AU (2) | AU2015315006B2 (enExample) |
| CA (2) | CA2960282C (enExample) |
| EA (1) | EA201790404A1 (enExample) |
| IL (2) | IL251045B (enExample) |
| MX (1) | MX2017003246A (enExample) |
| WO (1) | WO2016040683A1 (enExample) |
| ZA (1) | ZA201701545B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| CN105682666B (zh) | 2013-09-06 | 2021-06-01 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
| WO2015057250A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| IL249188B2 (en) * | 2014-05-27 | 2024-03-01 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
| KR20170010003A (ko) | 2014-05-27 | 2017-01-25 | 아카데미아 시니카 | 박테로이드 기원의 푸코시다제 및 이의 사용 방법 |
| KR20170003720A (ko) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | 항-ｃｄ20 글리코항체 및 이의 용도 |
| CN106714829A (zh) | 2014-05-28 | 2017-05-24 | 中央研究院 | 抗TNF‑α醣抗体及其用途 |
| KR102786695B1 (ko) | 2014-09-12 | 2025-03-25 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 대음세포작용 인간 항-cd46 항체 및 표적화된 암 치료제 |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| CA2972072A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
| WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| TWI764917B (zh) | 2016-08-22 | 2022-05-21 | 醣基生醫股份有限公司 | 抗體、結合片段及使用方法 |
| EP3538551A4 (en) * | 2016-11-10 | 2020-11-11 | Fortis Therapeutics, Inc. | CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF |
| US11434301B2 (en) | 2016-11-11 | 2022-09-06 | The Regents Of The University Of California | Anti-CD46 antibodies and methods of use |
| JP2020535171A (ja) * | 2017-09-27 | 2020-12-03 | ターグイミューン セラピューティクス アーゲー | 去勢抵抗性前立腺癌 |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| CN109535260B (zh) * | 2018-11-22 | 2021-08-10 | 东南大学 | 一种靶向cd46的人源嵌合抗原受体及其应用 |
| IL298902A (en) * | 2020-06-18 | 2023-02-01 | Bioatla Llc | Conditionally active anti-CD46 antibodies, antibody fragments, their immunoconjugates and their uses |
| CA3188728A1 (en) * | 2020-08-07 | 2022-02-10 | Marc Nasoff | Immunoconjugates targeting cd46 and methods of use thereof |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| AU2022205348A1 (en) * | 2021-01-07 | 2023-08-17 | Fortis Therapeutics, Inc. | Combination therapy with for46 for cancer |
| US20240101699A1 (en) * | 2021-01-07 | 2024-03-28 | The Regents Of The University Of California | Modulation of cd46 cell surface expression and therapeutic use thereof |
| EP4274612A4 (en) * | 2021-01-07 | 2025-08-13 | Univ California | MODULATION OF THE CELL SURFACE MARKER CD46 IN ANDROGEN RECEPTOR POSITIVE AND NEGATIVE CANCER CELLS |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| CN116189759B (zh) * | 2023-03-13 | 2025-05-06 | 南京农业大学 | 一种群体感应先导化合物的虚拟筛选方法及应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018097A1 (en) * | 1990-05-11 | 1991-11-28 | University Of Melbourne | Cd46 variants |
| US20020115065A1 (en) * | 2000-08-28 | 2002-08-22 | Ton Logtenberg | Differentially expressed epitopes and uses thereof |
| EP1184458A1 (en) * | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof |
| US7148038B2 (en) * | 2001-10-16 | 2006-12-12 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof |
| EP1482052A1 (en) * | 2003-05-27 | 2004-12-01 | Cytos Biotechnology AG | Modified polypeptides for targeting cell-entry of the adenoviruses of subtype B |
| JP2008534559A (ja) * | 2005-04-01 | 2008-08-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 血液凝固ｆｖｉｉｉ類似体 |
| WO2009039192A2 (en) * | 2007-09-17 | 2009-03-26 | The Regents Of The University Of Californina | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| KR20110096536A (ko) * | 2008-10-31 | 2011-08-30 | 애보트 바이오테라퓨틱스 코포레이션 | 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도 |
| AU2011295715B9 (en) * | 2010-09-03 | 2017-02-23 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
| WO2012075111A1 (en) * | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| ES2600081T3 (es) * | 2011-10-18 | 2017-02-07 | Csl Behring Gmbh | Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII |
| CN102863531A (zh) * | 2012-07-31 | 2013-01-09 | 张爱晖 | 一种抗cd20单克隆抗体及其制备方法和用途 |
| US9567402B2 (en) | 2013-03-14 | 2017-02-14 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate and other cancer cells |
| GB2513405A (en) * | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
| JP6522731B2 (ja) | 2014-03-21 | 2019-05-29 | ロエシェ ゲーエムベーハー | 多物質系の複合材を含む材料を前処理および分離するための方法およびデバイス |
| KR102786695B1 (ko) | 2014-09-12 | 2025-03-25 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 대음세포작용 인간 항-cd46 항체 및 표적화된 암 치료제 |
| KR20180073675A (ko) | 2015-11-10 | 2018-07-02 | 메디뮨 엘엘씨 | Asct2에 특이적인 결합 분자 및 이의 용도 |
| US11434301B2 (en) | 2016-11-11 | 2022-09-06 | The Regents Of The University Of California | Anti-CD46 antibodies and methods of use |
| SG11202108029XA (en) | 2019-01-28 | 2021-08-30 | Sanofi Sa | Methods of treating multiple myeloma |
| US20240101699A1 (en) | 2021-01-07 | 2024-03-28 | The Regents Of The University Of California | Modulation of cd46 cell surface expression and therapeutic use thereof |
| EP4274612A4 (en) | 2021-01-07 | 2025-08-13 | Univ California | MODULATION OF THE CELL SURFACE MARKER CD46 IN ANDROGEN RECEPTOR POSITIVE AND NEGATIVE CANCER CELLS |
| AU2022205348A1 (en) | 2021-01-07 | 2023-08-17 | Fortis Therapeutics, Inc. | Combination therapy with for46 for cancer |
-
2015
- 2015-09-10 KR KR1020237024940A patent/KR102786695B1/ko active Active
- 2015-09-10 CN CN202111212538.5A patent/CN114106179B/zh active Active
- 2015-09-10 CN CN201580061138.5A patent/CN107135654B/zh active Active
- 2015-09-10 US US15/508,059 patent/US10533056B2/en active Active
- 2015-09-10 JP JP2017513709A patent/JP6730260B2/ja active Active
- 2015-09-10 KR KR1020177009569A patent/KR102559731B1/ko active Active
- 2015-09-10 CA CA2960282A patent/CA2960282C/en active Active
- 2015-09-10 MX MX2017003246A patent/MX2017003246A/es unknown
- 2015-09-10 EP EP15839357.9A patent/EP3191524A4/en active Pending
- 2015-09-10 CA CA3225295A patent/CA3225295A1/en active Pending
- 2015-09-10 WO PCT/US2015/049492 patent/WO2016040683A1/en not_active Ceased
- 2015-09-10 EA EA201790404A patent/EA201790404A1/ru unknown
- 2015-09-10 AU AU2015315006A patent/AU2015315006B2/en active Active
-
2017
- 2017-03-02 ZA ZA2017/01545A patent/ZA201701545B/en unknown
- 2017-03-09 IL IL251045A patent/IL251045B/en active IP Right Grant
-
2019
- 2019-11-21 US US16/691,417 patent/US12325755B2/en active Active
-
2020
- 2020-06-30 JP JP2020113065A patent/JP7207753B2/ja active Active
-
2021
- 2021-04-05 IL IL282077A patent/IL282077B/en unknown
- 2021-08-03 AU AU2021211989A patent/AU2021211989B2/en active Active
-
2025
- 2025-05-09 US US19/204,124 patent/US20250333533A1/en active Pending